TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: STEM (Science, Technology, Engineering & Math) Familia Talk

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Latino parents and their children who are students in grades 3 through 6.~* Parents have Spanish as primary home language.~* Family has wi-fi in the home.~* No age limits for parents. Their child must be in grades 3 through 6.~Exclusion Criteria:~* Parents and their children who are students in grade levels below grade 3 or above grade 6.~* Parents do not have Spanish as primary home language.~* Family does not have wi-fi in the home.~* Children younger than 8 (or in grade levels below grade 3).

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Talk STEM Familia App (Type: EXPERIMENTAL): This arm will test the feasibility of the Talk STEM Familia app to improve English language acquisition and family engagement and promote long-term educational and health outcomes among first- and second-generation Latino families.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Learning to Apply Mindfulness to Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must have qualifying pain diagnoses on at least 2 occasions, at least 90 days apart, within the same pain category, during the previous 2 years~* Must report having a pain duration of ≥ 6 months (pain chronicity threshold), and a pain severity score of ≥ 4 on the 0-10 Numeric Rating Scale (pain severity threshold).~* Must have access to a smart phone that meets the requirement of the mobile app software~* Must be willing and able to download the mobile app on their phone~* Must have wireless or cellular internet access on a daily basis~* Must be willing to meet via video conference on the dates and at the time when Mobile+Group LAMP sessions are held, and attend all sessions of the arm to which they are randomized.~Exclusion Criteria:~* new diagnosis of schizophrenia, bipolar disorder, major depressive disorder, or other psychosis within the past 18 months; or current active psychotic symptoms, suicidality, severe depression, manic episode, and/or poorly controlled bipolar disorder (as assessed by a medical chart review)~* currently enrolled in a research study for pain~* currently enrolled in mindfulness-based stress reduction (MBSR)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mobile+Group LAMP Mindfulness-Based Intervention (Type: EXPERIMENTAL): 8 weekly, synchronous interactive online group sessions; access to mobile app and a study website, with an accompanying workbook.
- Mobile LAMP Mindfulness-Based Intervention (Type: EXPERIMENTAL): 8 weekly asynchronous sessions, delivered on mobile app and study website, with an accompanying workbook; 3 engagement calls at the middle, beginning and end of the program.
- Usual Care (Type: NO_INTERVENTION): Engagement in usual care for 12 months as participants normally would. After the entire follow-up period is complete (12 months), participants in the usual care arm are given access to the Mobile LAMP materials MBI training on the app and study website, and the accompanying workbook.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RIRS Versus ESWL for the Treatment of Renal Stones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* renal stone measuring 6 to 20 mm~* signing informed consent~* WHO performance status 0-2~Exclusion Criteria:~* Other stone \>5 mm~* concomitant ureteral stones~* BMI \> 35~* severe coagulopathy~* impossibility to sign informed consent~* pregnancy~* age \< 18 years old or \> 85

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- RIRS (retrograde intrarenal surgery) (Type: EXPERIMENTAL): In the first arm (RIRS) the patients will be treated by a standard retrograde ureterorenoscopy and Holmium laser lithotripsy. Preoperative exams will be abdomen ultrasound and Xray (CT in case of stones \> 15 mm), urine analysis and culture (according to all the more recent guidelines). Surgeries will be performed under general or spinal anesthesia, according to anesthesiologist evaluation. According with standard technique, ureteroscopy will be performed using both rigid and flexible ureteroscope. Lithotripsy will be performed by Holmium laser. Major stone fragments will be removed at the end of the procedure. Finally a double J ureteral stent will be push in specific cases depending on intraoperative findings (length of the procedure, macroscopic view of the ureter, residual stones etc.). RIRS will be an outpatients procedure with an hospital stay \<23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
- ESWL (extracorporeal shockwaves lithotripsy) (Type: EXPERIMENTAL): In the second arm (ESWL) the patients will be treated by a standard extracorporeal shock waves lithotripsy (ESWL). Preoperative exams will be the same as first arm. No general or spinal anaesthesia will be used, but just intravenous medications if required. Ultrasound and/or X-Ray will be used to locate the stone. Power and number of shock waves will consist in 20-24 KV and 3000-3500 sw respectively, according to individual tolerance. ESWL will be an outpatients procedure with an hospital stay \<23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Ulcerative Colitis (UC) for at least 90 days, confirmed by endoscopy during Screening period.~* Active UC with Mayo Score of 6 to 12 points and endoscopy subscore of 2 to 3 despite concurrent or prior treatment with a full and adequate course, in the opinion of the Investigator, with oral corticosteroids or immunosuppressants or both. Mayo Score is confirmed by central reader.~Exclusion Criteria:~* Subject with Crohn's disease (CD) or indeterminate colitis (IC).~* Current diagnosis of fulminant colitis and/or toxic megacolon.~* Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.~* Chronic recurring infections or active tuberculosis (TB).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Induction (Main Study + Japan Sub-study): I-SD (Type: EXPERIMENTAL): Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.
- Induction (Main Study + Japan Sub-study): I-HD (Type: EXPERIMENTAL): Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.
- Maintenance (Main Study + Japan Sub-study): M-SD (Type: EXPERIMENTAL): Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.
- Maintenance (Main Study + Japan Sub-study): M-HD (Type: EXPERIMENTAL): Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.
- Maintenance (Main Study): TDM Regimen (Type: EXPERIMENTAL): Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Documented or suspected cUTI/AP with clinical signs and symptoms~* Normal kidney function defined as creatinine clearance (CLcr) of ≥60mL/min using Cockcroft-Gault formula~Key Exclusion Criteria:~* Acute bacterial prostatis, orchitis, epididymitis, or chronic bacterial prostatis~* Gross heanaturia requiring intervention other than study drug~* Urinary tract surgery within 7 days of randomization or during the study period~* A known nonrenal source of infection diagnosed within 7 days of randomization~* A corrected QT interval \> 440 msec~* History of hearing loss with onset before the age of 40 years, sensorineural hearing loss, or family history of hearing loss~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- plazomicin (10 mg/kg) (Type: EXPERIMENTAL): Patients received two intravenous (IV) infusions daily for 5 consecutive days: 10 milligrams per kilogram (mg/kg) plazomicin followed by placebo.
- plazomicin (15 mg/kg) (Type: EXPERIMENTAL): Patients received two IV infusions daily for 5 consecutive days: 15 mg/kg plazomicin followed by placebo.
- levofloxacin (Type: ACTIVE_COMPARATOR): Patients received two IV infusions daily for 5 consecutive days: placebo followed by 750 milligrams (mg) levofloxacin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sexually active women, at risk for pregnancy and not planning to use condoms.~* Women in need for contraception and willing to use an oral contraceptive (OC) for 12 months (13 cycles).~* At least 18 but not older than 50 years of age at the time of screening.~* Body mass index (BMI) of \>/= 17 and \</= 35.~* Good physical and mental health.~* Willing to give informed consent in writing.~Exclusion Criteria:~* Contraindications for contraceptive steroids.~* In accordance with the Summary of Product Characteristics (SmPC)/Package Insert of DRSP-EE, additional~contraindications related to the antimineralocorticoid activity of drospirenone~(conditions that predispose to hyperkalemia):~* Renal insufficiency~* Hepatic dysfunction~* Adrenal insufficiency~* An abnormal cervical smear (i.e.: dysplasia, cervical intraepithelial neoplasia \[CIN\],~Squamous Intraepithelial Lesion \[SIL\], carcinoma in situ, invasive carcinoma) at screening.~* Clinically relevant abnormal laboratory result at screening as judged by the investigator.~* Use of an injectable hormonal method of contraception; within 6 months of an injection with a 3-month duration, within 4 months of an injection with a 2-month duration, within 2 months of an injection with a 1-month duration.~* Before spontaneous menstruation has occurred following a delivery or abortion.~* Breastfeeding or within 2 months after stopping breastfeeding prior to the start of trial medication.~* Present use or use within 2 months prior to the start of the trial medication of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex steroids (other than pre- and posttreatment contraceptive method) and herbal remedies containing Hypericum perforatum (St John's Wort).~* Administration of investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- NOMAC-E2 (Type: EXPERIMENTAL): Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2~monophasic combined oral contraceptive
- DRSP-EE (Type: ACTIVE_COMPARATOR): Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ovarian or primary peritoneal cancer confirmed by pathology~* Patients must have recurrent ovarian cancer which is sensitive to platinum therapy~* Prior radiation therapy is allowed~Measurable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines, or non-measurable but cancer antigen 125 (CA-125) greater than or equal to 2X upper limit.~Exclusion Criteria:~* More than 2 lines of therapy for ovarian or primary peritoneal cancer.~* Pregnant or breast feeding.~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed/Carboplatin Phase 1 (Type: EXPERIMENTAL): Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion.
- Pemetrexed/Carboplatin Phase 2 (Type: EXPERIMENTAL): Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 8-22 years~* Autosomal dominant polycystic kidney disease~* Normal kidney function~Exclusion Criteria:~* Abnormal kidney function~* Past allergic history to medications used in study~* Liver disease~* Muscle disease/dystrophy~* Pregnancy, planned pregnancy, or lactation within study period~* Inability to cooperate with or clinical contraindication for magnetic resonance imaging

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Pravastatin (Type: EXPERIMENTAL): Pravastatin
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Diagnosis of CD30+ classical Hodgkin lymphoma reconfirmed by histopathology. Note: where reconfirmation is not possible, patients will still be eligible where they have confirmation clearly documented in their medical records.~2. Relapsed or refractory disease after standard therapy including brentuximab vedotin (Adcetris®).~3. Completion of, if applicable, radiotherapy, chemotherapy, antibodies and immunoconjugates including brentuximab vedotin and/or another investigational drug which could interact with this trial not less than 4 weeks (or 5 half-lives of the drug, whichever occurs later) prior to first dose of study drug. Cessation of small molecule tyrosine kinase inhibitors must be at least 7 days prior to first dose of study drug.~4. Completion of, if applicable, an autologous stem cell transplantation (ASCT) at least 3 months prior to first dose of study drug.~5. Eastern Cooperative Oncology Group (ECOG) performance score (PS) \<2.~Main Exclusion Criteria:~1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.~2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if the patient has previously participated in MK-3475 clinical trials.~3. Has received a live-virus vaccination within 30 days of planned treatment start. Note: Seasonal flu vaccines that do not contain live virus are permitted.~4. Prior allogeneic stem cell transplantation (SCT) within the last 5 years.~5. Major surgery within 4 weeks prior to first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AFM13 + Pembrolizumab (Type: EXPERIMENTAL): Participants receive AFM13 in escalating doses intravenously (IV) for up to 25 weeks, pembrolizumab as a fixed dose intravenously (IV) for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~* Participants must have locally advanced or metastatic solid tumors.~* Participant is male or female greater than or equal to 18 years of age.~* Participant must have a performance status less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale~* Female participants of childbearing potential has a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication.~* Participants in the MK-2206 + carboplatin/paclitaxel and MK-2206 + docetaxel treatment arms will be limited to no more than 3 prior cytotoxic therapies for metastatic or recurrent diseases.~* Participant is able to swallow capsules and has no surgical or anatomical condition that will prevent the Participant from swallowing.~Exclusion Criteria:~* Participant has had chemotherapy, radiotherapy or biological therapy within 4 weeks.~* Participants must be least 4 weeks post-surgery and do not expect major surgery in the study duration.~* Participant is currently participating or has participated in a study with an investigational compound or device within 30 days.~* Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.~* Participant with a primary central nervous system tumor.~* Participant has known hypersensitivity to the components of study drug.~* Participant has a history or current evidence of heart disease.~* Participant has evidence of clinically significant bradycardia (slow heart rate).~* Participant has uncontrolled high blood pressure.~* Participant at significant risk for hypokalemia (low potassium levels).~* Participant is a known diabetic~* Participant has known psychiatric or substance abuse disorders.~* Participant is a user of illicit drugs.~* Participant is pregnant or breastfeeding.~* Participant is Human Immunodeficiency Virus (HIV) positive.~* Participant has known history of Hepatitis B or C or active Hepatitis A.~* Participant has symptomatic ascites or pleural effusion.~* Participant is receiving treatment with oral corticosteroids.~* Participant is using a potent cytochrome P(450) 3A4 (CYP3A4) inhibitor or inducer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-2206 + carboplatin + paclitaxel (Type: EXPERIMENTAL): MK-2206 combined with carboplatin and paclitaxel
- MK-2206 + docetaxel (Type: EXPERIMENTAL): MK-2206 combined with docetaxel plus pretreatment with a corticosteroid
- MK-2206 + erlotinib (Type: EXPERIMENTAL): MK-2206 combined with erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete